Result of AGM

RNS Number : 6628W

SkinBioTherapeutics PLC

23 December 2021

 

23 December 2021

SkinBioTherapeutics plc

Results of AGM

SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

Resolution		For & Discretionary		Against		Withheld
		Number of votes	%	Number of votes	%	Number of votes	%
01	Ordinary resolution to receive and adopt the 2021 Financial Statements	46,333,616	100.00%	Nil	0.00%	1,138	0.002%
02	Ordinary resolution to re-appoint Jeffreys Henry as auditors	46,319,786	99.97%	13,830	0.03%	1,138	0.002%
03	Ordinary resolution to re-elect Stuart Ashman as a director	46,325,446	99.98%	738	0.002%	8,570	0.018%
04	Ordinary resolution to re-elect Martin Hunt as a director	46,272,446	99.87%	738	0.002%	61,570	0.133%
05	Ordinary resolution to re-elect Dr Cathy Prescott as a director	46,272,446	99.87%	53,738	0.116%	8,570	0.018%
06	Ordinary resolution to re-elect Doug Quinn as a director	46,272,446	99.87%	738	0.002%	61,570	0.133%
07	Ordinary resolution to authorise the directors to allot shares	46,210,124	99.73%	103,919	0.224%	20,711	0.045%
08	Special resolution to authorise the directors to disapply pre-emption rights	46,162,274	99.63%	151,769	0.328%	20,711	0.045%
09	Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment	46,190,229	99.69%	123,814	0.267%	20,711	0.045%

-Ends-

For more information please contact:

SkinBioTherapeutics plc Stuart J . Ashman, CEO Doug Quinn, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson, Dale Bellis (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Nathan Billis	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .

 

END

 

 

RAGDKNBBBBDDPBB